The estimated Net Worth of Alexis V Lukianov is at least $21.5 Milion dollars as of 6 March 2015. Mr. Lukianov owns over 18,750 units of Orthofix Medical Inc stock worth over $6,039,836 and over the last 20 years he sold OFIX stock worth over $15,161,499. In addition, he makes $259,981 as Independent Director at Orthofix Medical Inc.
Alexis has made over 76 trades of the Orthofix Medical Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 18,750 units of OFIX stock worth $343,313 on 6 March 2015.
The largest trade he's ever made was exercising 139,000 units of Orthofix Medical Inc stock on 23 May 2007 worth over $87,570. On average, Alexis trades about 13,040 units every 36 days since 2004. As of 6 March 2015 he still owns at least 347,117 units of Orthofix Medical Inc stock.
You can see the complete history of Mr. Lukianov stock trades at the bottom of the page.
Alexis V. Lukianov is Independent Director of the Company. He became a director in December 2016, bringing to the Board his more than 30 years of experience in the orthopedic industry. He is Chairman and CEO of Tissue Differentiation Intelligence, LLC, a privately-held ultrasound spine company formed in 2017, and is Chairman and CEO of DuraStat, LLC, a privately-held surgical device company formed in 2017. From July 1999 to March 2015, he served as Chief Executive Officer and a director of NuVasive, Inc., a publicly-traded medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders, including serving as Chairman of the Board between 2004 and 2015. From April 1996 to April 1997, Mr. Lukianov was a founder of and served as Chairman of the Board and Chief Executive Officer of BackCare Group, Inc., a spine physician practice management company. From January 1990 to October 1995, Mr. Lukianov held a variety of senior executive positions, including President, with Medtronic Sofamor Danek, Inc., a developer and manufacturer of medical devices to treat disorders of the cranium and spine and a subsidiary of Medtronic, Inc., a publicly-traded medical technology company. Between 1987 and 1990, he was the director of a business unit at Smith & Nephew Orthopaedics that brought limb lengthening technology to the United States from Russia. From 2007 until its acquisition in 2015 by Royal Philips, he served on the Board of Directors of Volcano Corporation, a Nasdaq-listed medical technology company. He has previously served on the boards and the executive committees of BIOCOM, a regional life sciences trade association, the Medical Device Manufacturers Association (MDMA), a national trade association, and the California Health Institute (CHI). Mr. Lukianov also serves on a number of private and non-profit boards.
As the Independent Director of Orthofix Medical Inc, the total compensation of Alexis Lukianov at Orthofix Medical Inc is $259,981. There are 11 executives at Orthofix Medical Inc getting paid more, with Jon Serbousek having the highest compensation of $4,076,200.
Alexis Lukianov is 64, he's been the Independent Director of Orthofix Medical Inc since 2016. There are 2 older and 15 younger executives at Orthofix Medical Inc. The oldest executive at Orthofix Medical Inc is Ronald Matricaria, 77, who is the Independent Chairman of the Board.
Alexis's mailing address filed with the SEC is 3451 PLANO PKWY, , LEWISVILLE, TX, 75056.
Over the last 22 years, insiders at Orthofix Medical Inc have traded over $19,062,472 worth of Orthofix Medical Inc stock and bought 182,076 units worth $5,806,101 . The most active insiders traders include Stuart Essig, Charles R. Kummeth oraz Alexis V Lukianov. On average, Orthofix Medical Inc executives and independent directors trade stock every 53 days with the average trade being worth of $179,237. The most recent stock trade was executed by Kevin J. Kenny on 8 January 2024, trading 5,959 units of OFIX stock currently worth $103,687.
orthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing
Orthofix Medical Inc executives and other stock owners filed with the SEC include: